Acute Food INtake Effect of Hemp Protein (A FINEH Protein) Trial - Part 2

Acute Food INtake Effect of Hemp Protein (A FINEH Protein) Trial - Part 2 - Are Acute Effects of Hemp Protein on Blood Glucose and Appetite Insulin-dependent?

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02458027

Enrollment

Registered

2015-05-29

Start date

2015-07-31

Completion date

2016-07-13

Last updated

2023-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Prevention, Obesity Prevention

Brief summary

Detailed description

The objectives of this trial are to investigate whether the effects of hemp protein on glycemic and appetite control are insulin-dependent by measuring 1) blood glucose, insulin and appetite for one hour following consumption, 2) blood glucose, insulin and appetite following a fixed energy meal to determine the second meal effect of hemp protein versus soybean protein and a non-protein control. The objectives of this trial are to investigate whether the effects of hemp protein on glycemic and appetite control are insulin-dependent by measuring 1) blood glucose, insulin and appetite for one hour following consumption, 2) blood glucose, insulin and appetite following a fixed energy meal to determine the second meal effect of hemp protein versus soybean protein and a non-protein control.

Interventions

DIETARY_SUPPLEMENTHemp Shake

Hemp Protein

DIETARY_SUPPLEMENTHemp

Hemp Protein Shake

DIETARY_SUPPLEMENTSoybean Shake

Soybean Protein

DIETARY_SUPPLEMENTSoybean

Soybean Protein Shake

DIETARY_SUPPLEMENTControl

Non-Protein Shake

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Normoglycemic (\<5.6 mmol/L) * Body mass index (BMI) of 18.5-29.9 kg/m2.

Exclusion criteria

* Restrained eaters * Regularly skip breakfast * Smokers * Those on medications that may influence study outcomes or have experienced any gastrointestinal related health conditions/surgeries over the past year.

Design outcomes

Primary

Measure	Time frame	Description
Plasma Glucose and Insulin Concentrations	0-200 minutes	Measured in blood using intravenous catheter at 12 time points, used to calculate area under curve (AUC). Glucose will be determined by automated methods using Abbot Spectrum CCX Analyzer, and Insulin will be measured by commercially available RIA kits. (Composite measure)
Appetite	0-200 minutes	Measured by VAS Questionnaire.
Food Intake	0-200 minutes	Measured by fixed energy meal.
Blood Pressure	0-200 minutes	Measured by automated bood pressure cuff.

Secondary

Measure	Time frame	Description
Physical Comfort	0-200 minutes	Measured by VAS Questionnaire.
Energy/Fatigue	0-200 minutes	Measured by VAS Questionnaire.
Palatability of Treatments and Meal	5-80 minutes	Measured by VAS Questionnaire.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 16, 2026